Peptidyl-prolyl cis-trans isomerase FKBP1A-calcineurin complex (FKBP12-calcineurin)

The FKBP12-calcineurin complex is a critical signaling assembly in the immune system, primarily responsible for the activation of T-lymphocytes [1, 2]. It consists of the immunophilin FKBP12 (Peptidyl-prolyl cis-trans isomerase FKBP1A) and the calcium-dependent serine/threonine protein phosphatase, calcineurin [2, 3]. Tacrolimus (FK506) acts as a molecular glue, binding to FKBP12 to form a gain-of-function complex that subsequently binds to and inhibits calcineurin [4, 5]. This inhibition prevents the dephosphorylation of the Nuclear Factor of Activated T-cells (NFAT), a transcription factor required for the expression of interleukin-2 (IL-2) and other cytokines [1, 5]. By blocking the NFAT pathway, the complex effectively suppresses T-cell mediated immune responses [1, 4]. This mechanism is a cornerstone of immunosuppressive therapy used to prevent organ transplant rejection and treat autoimmune conditions like atopic dermatitis and psoriasis [1, 4]. Therapeutic use of drugs targeting this complex requires careful monitoring due to significant side effects, including nephrotoxicity and neurotoxicity [1, 4]. The complex represents a classic example of how small molecules can modulate protein-protein interactions to achieve therapeutic effects [5].

Other names

FKBP12-calcineurin complexFK506-binding protein 12Protein phosphatase 2BPP2BFKBP1A-PPP3CA-PPP3R1 complex

Tacrolimus binds to FKBP12 to form a complex that sterically inhibits the phosphatase activity of calcineurin, preventing NFAT dephosphorylation and subsequent T-cell activation.